Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases

Journal of Immunology

Volumn 179, Issue 3, 2007, Pages 1960-1968

  Yu, Ping ^a   Lee, Youjin ^a   Wang, Yang ^a   Liu, Xiaojuan ^a   Auh, Sogyong ^a   Gajewski, Thomas F ^a   Schreiber, Hans ^a   You, Zhaoyang ^b   Kaynor, Campbell ^c   Wang, Xinzhong ^c   Fu, Yang Xin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; HERPESVIRUS ENTRY MEDIATOR LIGAND; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER LOCALIZATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; FEMALE; FIBROSARCOMA; HOST RESISTANCE; IMMUNE RESPONSE; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; C3H MOUSE; C57BL MOUSE; COLON TUMOR; CYTOLOGY; CYTOTOXICITY; EXPERIMENTAL MELANOMA; EXPERIMENTAL NEOPLASM; GENE VECTOR; GENETICS; GRAFT REJECTION; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; LUNG TUMOR; LYMPHOCYTE ACTIVATION; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENETIC VECTORS; GRAFT REJECTION; HUMANS; IMMUNITY, NATURAL; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14;

EID: 34548646455     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.3.1960     Document Type: Article

References (33)

1. Fidler, I. J. 2003. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat. Rev. Cancer 3: 453-458.
2. Koscielny, S., M. Tubiana, M. G. Le, A. J. Valleron, H. Mouriesse, G. Contesso, and D. Sarrazin. 1984. Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br. J. Cancer 49: 709-715.
3. Koscielny, S., M. Tubiana, and A. J. Valleron. 1985. A simulation model of the natural history of human breast cancer. Br. J. Cancer 52: 515-524.
4. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183: 725-729.
5. Rosenberg, S. A. 1999. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10: 281-287.
6. Schreiber, H. 2003. Tumor immunology. In Fundamental Immunology, W. E. Paul, ed. Lippincott Raven Press, New York, pp. 1557-1592.
7. Rosenberg, S. A. 2005. The emergence of modern cancer immunotherapy. Ann. Surg. Oncol. 12: 344-346.
8. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
9. Mauri, D. N., R. Ebner, R. I. Montgomery, K. D. Kochel, T. C. Cheung, G. L. Yu, S. Ruben, M. Murphy, R. J. Eisenberg, G. H. Cohen, et al. 1998. LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator. Immunity 8: 21-30.
10. Wang, J., A. Foster, R. Chin, P. Yu, Y. Sun, Y. Wang, K. Pfeffer, and Y. X. Fu. 2002. The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function. Eur. J. Immunol. 32: 1969-1979.
11. Tamada, K., K. Shimozaki, A. I. Chapoval, G. Zhu, G. Sica, D. Flies, T. Boone, H. Hsu, Y. X. Fu, S. Nagata, et al. 2000. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat. Med. 6: 283-289.
12. Ware, C. F. 2005. Network communications: lymphotoxins, LIGHT, and TNF. Annu. Rev. Immunol. 23: 787-819.
13. Wang, J., R. A. Anders, Y. Wang, J. R. Turner, C. Abraham, K. Pfeffer, and Y. X. Fu. 2005. The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease. J. Immunol. 174: 8173-8182.
14. Yu, P., Y. Lee, W. Liu, R. K. Chin, J. Wang, Y. Wang, A. Schietinger, M. Philip, H. Schreiber, and Y. X. Fu. 2004. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 5: 141-149.
15. Debes, G. F., C. N. Arnold, A. J. Young, S. Krautwald, M. Lipp, J. B. Hay, and E. C. Butcher. 2005. Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nat. Immunol. 6: 889-894.
16. Bromley, S. K., S. Y. Thomas, and A. D. Luster. 2005. Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. Nat. Immunol. 6: 895-901.
17. Wick, M., P. Dubey, H. Koeppen, C. T. Siegel, P. E. Fields, L. Chen, J. A. Bluestone, and H. Schreiber. 1997. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186: 229-238.
18. + T cells. Cancer Res. 64: 1140-1145.
19. Miller, F. R., B. E. Miller, and G. H. Heppner. 1983. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 3: 22-31.
20. Coligan, J. E., A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober. 1991. Current Protocols in Immunology. John Wiley and Sons, pp. 20.2.1-20.2.11.
21. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201: 779-791.
22. + T cells. J. Exp. Med. 197: 985-995.
23. Barber, D. L., E. J. Wherry, and R. Ahmed. 2003. Cutting edge: rapid in vivo killing by memory CD8 T cells. J. Immunol. 171: 27-31.
24. Parviz, M., C. S. Chin, L. J. Graham, C. Miller, C. Lee, K. George, and H. D. Bear. 2003. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model. Cancer Immunol. Immunother. 52: 739-750.
25. Pulaski, B. A., and S. Ostrand-Rosenberg. 1998. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493.
26. Kocak, E., K. Lute, X. Chang, K. F. May, Jr., K. R. Exten, H. Zhang, S. F. Abdessalam, A. M. Lehman, D. Jarjoura, P. Zheng, and Y. Liu. 2006. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 66: 7276-7284.
27. Wilcox, R. A., D. B. Flies, G. Zhu, A. J. Johnson, K. Tamada, A. I. Chapoval, S. E. Strome, L. R. Pease, and L. Chen. 2002. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109: 651-659.
28. + cytotoxic T lymphocytes in association with a class I MHC protein. Cell 69: 989-998.
29. Bai, X. F., J. X. Gao, J. Liu, J. Wen, P. Zheng, and Y. Liu. 2001. On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen. Cancer Res. 61: 6860-6867.
30. Ochsenbein, A. F., S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, and R. M. Zinkernagel. 2001. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411: 1058-1064.
31. Harrop, J. A., P. C. McDonnell, M. Brigham-Burke, S. D. Lyn, J. Minton, K. B. Tan, K. Dede, J. Spampanato, C. Silverman, P. Hensley, et al. 1998. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J. Biol. Chem. 273: 27548-27556.
32. Zhai, Y., R. Guo, T. L. Hsu, G. L. Yu, J. Ni, B. S. Kwon, G. W. Jiang, J. Lu, J. Tan, M. Ugustus, et al. 1998. LIGHT, a novel ligand for lymphotoxin β receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J. Clin. Invest. 102: 1142-1151.
33. Browning, J. L., K. Miatkowski, I. Sizing, D. Griffiths, M. Zafari, C. D. Benjamin, W. Meier, and F. Mackay. 1996. Signaling through the lymphotoxin β receptor induces the death of some adenocarcinoma tumor lines. J. Exp. Med. 183: 867-878.